Menu12/2/14: For folks who missed the Pinsent Masons regulatory conference in London this fall, Richard Cassin gives an overview on his FCPA blog of David Green’s comments (the chief of the UK Serious Fraud Office). Green admitted that fraud was up – an all-too-familiar reality for compliance professionals – but so is enforcement by the UK’s Serious...
Compliance Communications Blog
Compliance Wave
Recent Posts
Dec 02, 2014 •
12/2/14: For folks who missed the Pinsent Masons regulatory conference in London this fall, Richard Cassin gives an overview on his FCPA blog of David Green’s comments (the chief of the UK Serious Fraud Office). Green admitted that fraud was up – an all-too-familiar reality for compliance professionals – but so is enforcement by the UK’s Serious...
Nov 15, 2014 •
11/15/14: Bid-rigging has become a familiar antitrust crime but the guilty plea by Aisin Seiki Co. Ltd., a Japan-based automotive parts manufacturer, resulted from its role in a conspiracy to allocate customers. That plea agreement is costing the company $35.8 million. The scheme, according to the US DOJ, involved meetings and conversations between...
Nov 01, 2014 •
11/1/14: In his Conflicts of Interest blog, Jeff Kaplan posted an article drawn from the keynote address given by Marshall Miller from DOJ’s Criminal Division Practicing Law Institute’s Advanced Compliance & Ethics Workshop. Kaplan quotes Miller about a high-level commitment as a principal hallmark of an effect compliance and ethics...
Oct 15, 2014 •
10/15/14: Business fraud isn’t just an occasional thing that happens to someone else. It’s distressingly common and it’s expensive. An article by Heather Raftery and Frank L. Holder published on the FTI Journal website and reprinted by Business Ethics Magazine digs into the disturbing reality of fraud, which is estimated to have cost...
Oct 15, 2014 •
10/15/14: The US Department of recently filed suit against a pharmaceutical company and its founder, owner and Chairman of the Board for violations to the Federal Food, Drug and Cosmetic Act (FD&CA) by manufacturing and distributing “adulterated and misbranded medical devices.” By itself, DOJ’s decision isn’t groundbreaking news but...
